Trials that use: Risk ratio / relative risk
New to this method? Read the tutorial →
6,204 results
- Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01147068).
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: primary endpoint results, effect…
- Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: primary endpoint results, effect estimate with…
- Safety and Immunogenicity Study of Na-GST-1 With or Without CpG: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Na-GST-1 With or Without CpG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02143518).
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04074928).
- Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Performance Study of the Harpoon Mitral Valve Repair System: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Study of the Harpoon Mitral Valve Repair System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): primary endpoint results, effect estimate with…
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00845650).
- Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV Vaccine (PoliorixTM) in Toddlers: Complete Statistical AnalysisIndependent statistical analysis of Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055): Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Tolerability of Seroguard Use: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Seroguard Use: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03640559).
- Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Tolerability Study of N6022 in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of N6022 in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01147406).
- Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.: Complete Statistical AnalysisIndependent statistical analysis of Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy: Complete Statistical AnalysisIndependent statistical analysis of Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Tolerability Study of SHP626 in Overweight and Obese Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability Study of SHP626 in Overweight and Obese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device: Complete Statistical AnalysisIndependent statistical analysis of Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01708213).
- Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy: Complete Statistical AnalysisIndependent statistical analysis of Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety of 4CMenB Exposure During Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Safety of 4CMenB Exposure During Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02640677).